Sanofi
SNY
40.20
+0.64
+1.62%
Sanofi
US · SNY
#211 by market cap
Listed 1970
40.20
+0.64
+1.62%
Live - 5344 symbols - heartbeat 134s ago
· 2026-10-08 08:15
Pre-market
39.95
-0.62%
After-hours
40.20
0.00%
Overnight
39.95
-0.62%
- Market cap
- 96.32B
- P/E (TTM)i
- 21.97
- P/Bi
- 1.24
- EPSi
- 3.57
- Div yieldi
- 5.88%
- 52W posi
- 10%
Reader sentiment
Are you bullish or bearish on SNY?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Margins
- Gross margin
- 72.07%
- Operating margin
- 20.54%
- Net margin
- 16.72%
Key ratios & quality
- Enterprise valuei
- 106.72B
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | 24.24B | 25.65B | 25.21B | 26.92B | 28.68B | 28.99B | 31.08B | 33.67B |
| Selling & admin expenses | 9.86B | 9.88B | 9.39B | 9.56B | 8.74B | 9.48B | 9.82B | 10.24B |
| Research & development | 5.89B | 6.02B | 5.53B | 5.69B | 6.50B | 6.51B | 7.39B | 7.84B |
| Operating profit | 6.26B | 7.18B | 7.89B | 9.15B | 10.93B | 8.69B | 8.92B | 9.60B |
| Pretax profit | 4.41B | 2.75B | 13.78B | 7.80B | 9.94B | 6.25B | 6.70B | 6.18B |
| Tax | 481.00M | 121.00M | 1.81B | 1.56B | 1.91B | 1.02B | 1.20B | 1.04B |
| Net profit | 4.41B | 2.79B | 12.33B | 6.28B | 8.48B | 5.44B | 5.62B | 7.85B |
| Basic EPS | 2 | 1 | 5 | 2 | 3 | 2 | 2 | 3 |
| Diluted EPS | 1.72 | 1.10 | 4.88 | 2.48 | 3.33 | 2.15 | 2.22 | 3.19 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | 7.72B | 7.74B | 9.76B | 8.45B | 8.11B | 9.28B |
| Selling & admin expenses | 2.39B | 2.46B | 2.29B | 3.45B | 2.49B | 2.63B |
| Research & development | 1.81B | 1.91B | 1.83B | 2.29B | 1.75B | 2.23B |
| Operating profit | 2.23B | 1.94B | 3.79B | 1.63B | 2.27B | 2.38B |
| Pretax profit | 2.16B | 1.42B | 3.51B | -917.00M | 2.00B | 837.00M |
| Tax | 481.00M | 230.00M | 680.00M | -348.00M | 420.00M | 451.00M |
| Net profit | 1.89B | 3.94B | 2.81B | -794.00M | 1.62B | 377.00M |
| Basic EPS | 1 | 2 | 1 | 0 | 1 | 0 |
| Diluted EPS | 0.76 | 1.62 | 1.15 | -0.33 | 0.67 | 0.15 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 24.65B | 28.94B | 30.65B | 30.65B | 34.11B | 30.67B | 42.59B | 30.95B |
| Cash & ST investments | 7.12B | 9.85B | 11.15B | 11.15B | 13.40B | 8.98B | 7.93B | 8.47B |
| Inventory | 7.48B | 7.99B | 8.72B | 8.72B | 8.96B | 9.67B | 9.43B | 10.21B |
| Total assets | 111.41B | 112.63B | 120.24B | 120.24B | 126.72B | 126.46B | 132.80B | 126.81B |
| Total current liabilities | 17.38B | 20.39B | 21.30B | 21.30B | 23.97B | 24.21B | 29.16B | 28.35B |
| Short-term debt | 2.63B | 4.82B | 3.45B | 3.45B | 4.45B | 2.32B | 4.47B | 4.61B |
| Long-term debt | 22.01B | 20.13B | 17.12B | 17.12B | 14.86B | 14.35B | 11.79B | 14.25B |
| Total liabilities | 52,373,000,000.00 | 53,400,000,000.00 | 51,211,000,000.00 | 51,211,000,000.00 | 51,570,000,000.00 | 52,111,000,000.00 | 54,941,000,000.00 | 55,095,000,000.00 |
| Total equity | 59.04B | 59.23B | 69.03B | 69.03B | 75.15B | 74.35B | 77.86B | 71.71B |
| Retained earnings | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 44.02B | 37.02B | 34.04B | 30.95B | 30.16B | 31.52B |
| Cash & ST investments | 7.99B | 15.36B | 8.91B | 8.47B | 5.54B | 6.35B |
| Inventory | 21.85B | 9.62B | 24.50B | 10.21B | 23.50B | 24.12B |
| Total assets | 131.89B | 124.96B | 129.79B | 126.81B | 128.02B | 129.06B |
| Total current liabilities | 32.22B | 29.06B | 32.11B | 28.35B | 30.01B | 31.93B |
| Short-term debt | 7.64B | 7.56B | 8.49B | 4.61B | 6.18B | 7.25B |
| Long-term debt | 11.77B | 13.20B | 11.70B | 14.25B | 12.30B | 14.65B |
| Total liabilities | 57,474,000,000.00 | 54,680,000,000.00 | 56,261,000,000.00 | 55,095,000,000.00 | 54,881,000,000.00 | 59,493,000,000.00 |
| Total equity | 74.42B | 70.28B | 73.53B | 71.71B | 73.14B | 69.57B |
| Retained earnings | -- | -- | -- | -- | -- | -- |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 5.55B | 7.72B | 7.42B | 10.52B | 10.53B | 10.26B | 9.08B | 10.75B |
| Depreciation & amortization | 4.28B | 7.45B | 3.67B | 3.35B | 3.11B | 4.43B | 3.59B | 5.68B |
| Free cash flow | 3.57B | 5.93B | 5.34B | 8.48B | 8.42B | 7.35B | 5.89B | 7.21B |
| Dividends paid | -3.77B | -3.83B | -3.94B | -4.01B | -4.17B | -4.45B | -4.70B | -4.77B |
| Stock buybacks / issuance | -924.00M | 153.00M | -619.00M | -196.00M | -309.00M | -398.00M | -115.00M | -4.85B |
| Ending cash balance | 6.93B | 9.43B | 13.92B | 10.10B | 12.74B | 8.71B | 7.44B | 7.66B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 2.09B | 1.46B | 3.75B | 3.45B | 1.68B | 2.96B |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | 2.09B | 1.46B | 3.75B | -93.00M | 1.68B | 1.66B |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 7.99B | 15.36B | 8.91B | 7.66B | 5.54B | 6.35B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 7.36 | 4.76 | 20.20 | 9.45 | 11.67 | 7.26 | 7.34 | 10.50 |
| ROA %i | 4.08 | 2.50 | 10.84 | 5.30 | 6.78 | 4.27 | 4.29 | 6.02 |
| ROIC %i | 5.79 | 3.68 | 14.69 | 7.32 | 9.15 | 5.82 | 6.21 | 8.61 |
| 5-year avg ROE %i | 9.07 | 8.45 | 10.80 | 11.23 | 10.40 | 10.38 | 10.91 | 9.16 |
| EBIT margin %i | 13.57 | 8.68 | 38.11 | 20.93 | 24.00 | 16.82 | 16.82 | 14.56 |
| FCF / sales %i | 10.01 | 15.75 | 14.28 | 21.64 | 18.34 | 15.58 | 13.29 | 15.44 |
| Current ratioi | 1.42 | 1.42 | 1.75 | 1.44 | 1.42 | 1.27 | 1.46 | 1.09 |
| Quick ratioi | 0.95 | 0.98 | 1.28 | 0.98 | 1.01 | 0.83 | 0.64 | 0.69 |
| Debt / assetsi | 22.12 | 23.02 | 20.69 | 18.64 | 16.74 | 14.57 | 13.48 | 16.03 |
| LT debt / equityi | 37.38 | 35.76 | 32.76 | 27.61 | 22.41 | 21.75 | 17.34 | 22.02 |
| Interest coveragei | 11.13 | 7.36 | 32.66 | 20.35 | 23.08 | 11.85 | 9.94 | 10.86 |
| Revenue CAGR (3Y) %i | 0.77 | 2.74 | 1.05 | 3.17 | 2.53 | 3.65 | 4.17 | 4.82 |
| Net income CAGR (3Y) %i | 0.15 | -16.37 | 13.47 | 13.06 | 44.86 | -23.98 | -3.69 | -2.27 |
| FCF CAGR (3Y) %i | -16.57 | -0.95 | -0.54 | 33.42 | 12.42 | 11.28 | -11.46 | -5.04 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 8.50 | 12.79 | 12.44 | 10.50 | 10.29 | 5.69 |
| ROA %i | 4.78 | 7.17 | 7.02 | 6.02 | 5.81 | 3.12 |
| ROIC %i | 6.93 | 9.95 | 9.76 | 8.61 | 8.29 | 4.65 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 18.68 | 18.55 | 18.31 | 14.56 | 13.96 | 12.60 |
| FCF / sales %i | 17.47 | 18.37 | 17.25 | 15.44 | 14.36 | 14.32 |
| Current ratioi | 1.37 | 1.27 | 1.06 | 1.09 | 1.01 | 0.99 |
| Quick ratioi | 0.26 | 0.81 | 0.29 | 0.69 | 0.20 | 0.21 |
| Debt / assetsi | 15.96 | 17.83 | 16.76 | 16.03 | 15.64 | 18.27 |
| LT debt / equityi | 18.10 | 21.03 | 18.11 | 22.02 | 19.01 | 23.59 |
| Interest coveragei | 11.80 | 12.76 | 16.86 | 10.86 | 11.19 | 8.44 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- BioPharma is the largest reported line at 99.03% of revenue, across 2 reported segments.
- The next-largest line, Other, is a distant second at 0.97% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
BioPharma99.03%
Other0.97%
Quote time 2026-10-08 08:15:20 · For reference only, not investment advice and not tailored to your situation.